Our Drug Discovery AI platform leverages deep learning and generative models to accelerate the identification and optimization of novel therapeutic candidates.
What we offer:
Virtual screening of compound libraries
Target identification and validation using multi-omics evidence
Drug repurposing – finding new uses for existing compounds
Structure-based and ligand-based drug design
By integrating genomic, proteomic, and metabolomic data, we prioritize drug targets with strong molecular evidence and predict patient populations most likely to respond.
This service supports pharmaceutical R&D, biotech startups, and academic drug discovery programs seeking to reduce the time and cost of bringing new therapies to clinic.
Our Multi-Omics Integration platform combines genomics, transcriptomics, proteomics, metabolomics, and medical imaging data into a unified analytical framework—revealing biological insights that single-omics approaches cannot achieve.
What we offer:
Integrative analysis of multi-omics datasets from the same cohort
AI-driven biomarker discovery across molecular layers
Pathway and network biology mapping
Radiogenomics – imaging phenotypes linked to molecular signatures
By applying advanced machine learning to multi-dimensional biological data, we identify novel disease subtypes, predictive biomarkers, and therapeutic targets that are validated across multiple independent data sources.
This service is ideal for large-scale precision medicine studies, translational research programs, and pharmaceutical collaborations seeking to uncover robust, clinically actionable insights.
Our Biomarker Discovery platform identifies and validates molecular signatures that predict disease risk, progression, or treatment response—from discovery through to clinical validation.
What we offer:
Discovery-phase biomarker identification from multi-omics data
Statistical validation and reproducibility testing
Machine learning-based signature refinement
Translational readiness assessment
We prioritize biomarkers that are biologically interpretable, statistically robust, and technically feasible for clinical assay development.
This service supports diagnostic developers, pharmaceutical companies, and academic researchers seeking to translate molecular discoveries into clinical tools.
Our Drug Discovery AI platform leverages deep learning and generative models to accelerate the identification and optimization of novel therapeutic candidates.
What we offer:
Virtual screening of compound libraries
Target identification and validation using multi-omics evidence
Drug repurposing – finding new uses for existing compounds
Structure-based and ligand-based drug design
By integrating genomic, proteomic, and metabolomic data, we prioritize drug targets with strong molecular evidence and predict patient populations most likely to respond.
This service supports pharmaceutical R&D, biotech startups, and academic drug discovery programs seeking to reduce the time and cost of bringing new therapies to clinic.
Our Multi-Omics Integration platform combines genomics, transcriptomics, proteomics, metabolomics, and medical imaging data into a unified analytical framework—revealing biological insights that single-omics approaches cannot achieve.
What we offer:
Integrative analysis of multi-omics datasets from the same cohort
AI-driven biomarker discovery across molecular layers
Pathway and network biology mapping
Radiogenomics – imaging phenotypes linked to molecular signatures
By applying advanced machine learning to multi-dimensional biological data, we identify novel disease subtypes, predictive biomarkers, and therapeutic targets that are validated across multiple independent data sources.
This service is ideal for large-scale precision medicine studies, translational research programs, and pharmaceutical collaborations seeking to uncover robust, clinically actionable insights.
Our Biomarker Discovery platform identifies and validates molecular signatures that predict disease risk, progression, or treatment response—from discovery through to clinical validation.
What we offer:
Discovery-phase biomarker identification from multi-omics data
Statistical validation and reproducibility testing
Machine learning-based signature refinement
Translational readiness assessment
We prioritize biomarkers that are biologically interpretable, statistically robust, and technically feasible for clinical assay development.
This service supports diagnostic developers, pharmaceutical companies, and academic researchers seeking to translate molecular discoveries into clinical tools.